HBIO News & Events

Reaffirms FY26 adjusted gross margin outlook between 58%060% and adjusted EBITDA growth between 6%-10%.

Sees Q2 adjusted gross margin between 57%-59%. Sees Q2 adjusted EBITDA between $1M-$2M. Expects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance.

Reports Q1 revenue $20.8M vs. $21.8M last year. The company noted encouraging adoption rates within its NPI portfolio, specifically the MeshMEA organoid platform and BTX Electroporation systems, which is driving a shift toward a higher-margin product mix. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said CEO John Duke.